Earnings call briefThird-quarter 2026
Vertex Pharmaceuticals lifts 2026 non-GAAP expense outlook to about $6 billion
The company attributes the increase to about $250 million of Crinetics operating and integration costs, with standalone spending at the high end of the prior range.
GetSignal Vertex Pharmaceuticals VRTX
Vertex Pharmaceuticals said on its third-quarter call it now expects combined non-GAAP operating expenses of approximately $6 billion for 2026, up from $5.65 billion to $5.75 billion.
The company also expects total nonoperating costs of $105 million for 2026 related to the financing of Crinetics. Vertex Pharmaceuticals said interest income is projected to be approximately $60 million lower than it otherwise would have been.
Quotes from the call
“On operating expenses, we are revising our prior combined non GAAP operating expense guidance of $5.65 billion to $5.75 billion to a revised estimate of approximately $6 billion.”
Key facts from the call
- 2026 non-GAAP operating expense outlook
- Approximately $6 billion, up from $5.65 billion to $5.75 billion
- Crinetics operating and integration costs in outlook
- Approximately $250 million
- 2026 nonoperating costs outlook
- $105 million, related to the financing of Crinetics
- Interest income outlook
- Approximately $60 million lower than it otherwise would have been, due to lower cash balances after the acquisition
Source: Vertex Pharmaceuticals' third-quarter 2026 earnings call, November 2, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Vertex says it now expects 2026 revenue of $13.1 billion to $13.2 billion
VRTX Vertex Pharmaceuticals Q2 2026 call
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
